5 Top Stock Gainers for Tuesday: Vaxart, Precipio, Gartner

Vaxart, Precipio, Gartner, Domtar and BioLineRX are five top stock gainers for Tuesday.
Author:
Publish date:

Stocks finished mixed Tuesday as investors rotated out of shares of tech companies and headed for higher-yielding value stocks.

Here are some of the top gainers for Tuesday:

1. Vaxart | Increase 9.2%

Shares of Vaxart  (VXRT) - Get Report jumped after the drugmaker said its oral COVID-19 vaccine treatment could be just as effective as the injectables made by its most popular rivals. 

The biopharma reported broad cross-reactivity against coronaviruses.

2. Precipio | Increase 7.7%

Precipio  (PRPO) - Get Report continued to climb, one day after the medical diagnostics company said it had launched its COVID-19 rapid antibody test on Amazon's  (AMZN) - Get Report business platform. 

The test is the first U.S.-based test to receive emergency-use authorization from the Food and Drug Administration for the point of care.

3. Gartner | Increase 14%

Gartner  (IT) - Get Report was surging after the research and advisory company reported better-than-expected first-quarter earnings. 

Gartner reported income of $164.1 million, or $1.84 a share, more than double the $75 million, or 83 cents a share, of a year earlier.

4. Domtar | Increase 19%

Shares of Domtar  (UFS) - Get Report jumped after the paper products company confirmed news reports that it had been in discussions with privately held Canadian company Paper Excellence about a possible acquisition or business combination. 

Domtar said the "discussions may or may not result in an agreement." 

5. BioLineRX | Increase 53%

BioLineRX  (BLRX) - Get Report leaped after the biopharma announced positive results from a Phase 3 trial of Motixafortide, its treatment for multiple myeloma patients. The company said the study met all primary and secondary endpoints with an exceptionally high level of statistical significance.

Amazon is a holding in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells AMZN? Learn more now.